Sutro Biopharma (STRO) Cash & Current Investments (2016 - 2026)

Sutro Biopharma has reported Cash & Current Investments for 10 years, with the latest figure at $141.4 million in Q4 2025.

• Quarterly Cash & Current Investments fell 55.37% year-over-year to $141.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $141.4 million (down 55.37% YoY) and the FY2025 annual result came in at $141.4 million, down 55.37% from the prior year.
• Cash & Current Investments retreated to $141.4 million in Q4 2025 per STRO's latest filing, from $167.6 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $388.3 million in Q3 2024 and troughed at $66.6 million in Q1 2022.
• A 5-year average of $218.5 million and a median of $212.7 million in 2021 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments plunged 69.74% in 2022, then surged 277.32% in 2023.
• Over 5 years, Cash & Current Investments stood at $160.8 million in 2021, then soared by 88.08% to $302.3 million in 2022, then slumped by 63.22% to $111.2 million in 2023, then soared by 184.96% to $316.9 million in 2024, then tumbled by 55.37% to $141.4 million in 2025.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $141.4 million, $167.6 million, and $205.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.